These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency. Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728 [TBL] [Abstract][Full Text] [Related]
12. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection. Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881 [TBL] [Abstract][Full Text] [Related]
13. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191 [TBL] [Abstract][Full Text] [Related]
14. Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States. Johnson J; Zhai Y; Salimi H; Espy N; Eichelberger N; DeLeon O; O'Malley Y; Courter J; Smith AB; Madani N; Sodroski J; Haim H J Virol; 2017 Aug; 91(15):. PubMed ID: 28490588 [TBL] [Abstract][Full Text] [Related]
15. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. Li Y; Bai H; Sanders-Buell E; Dussupt V; Townsley S; Donofrio G; Bose M; O'Sullivan AM; Kibuuka H; Maganga L; Nitayaphan S; Kosgei J; Pitisuttithum P; Rerks-Ngarm S; Eller LA; Michael NL; Robb ML; Ake J; Vasan S; Tovanabutra S; Krebs SJ; Rolland M J Virol; 2021 Aug; 95(17):e0079721. PubMed ID: 34160251 [TBL] [Abstract][Full Text] [Related]
16. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants. Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354 [TBL] [Abstract][Full Text] [Related]
17. Antibodies targeting the fusion peptide on the HIV envelope provide protection to rhesus macaques against mucosal SHIV challenge. Pegu A; Lovelace SE; DeMouth ME; Cully MD; Morris DJ; Li Y; Wang K; Schmidt SD; Choe M; Liu C; Chen X; Viox E; Rowshan A; Taft JD; Zhang B; Xu K; Duan H; Ou L; Todd JP; Kong R; Li H; Shaw GM; Doria-Rose NA; Kwong PD; Koup RA; Mascola JR Sci Transl Med; 2024 Jan; 16(730):eadh9039. PubMed ID: 38232141 [TBL] [Abstract][Full Text] [Related]
18. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time. Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804 [TBL] [Abstract][Full Text] [Related]
19. VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. Shen CH; DeKosky BJ; Guo Y; Xu K; Gu Y; Kilam D; Ko SH; Kong R; Liu K; Louder MK; Ou L; Zhang B; Chao CW; Corcoran MM; Feng E; Huang J; Normandin E; O'Dell S; Ransier A; Rawi R; Sastry M; Schmidt SD; Wang S; Wang Y; Chuang GY; Doria-Rose NA; Lin B; Zhou T; Boritz EA; Connors M; Douek DC; Karlsson Hedestam GB; Sheng Z; Shapiro L; Mascola JR; Kwong PD Cell Host Microbe; 2020 Apr; 27(4):531-543.e6. PubMed ID: 32130953 [TBL] [Abstract][Full Text] [Related]
20. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]